Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. METHODS: We randomly assigned adults in a 1:1 ratio to receive either nivolumab (3 mg per kilogram of body weight) plus ipilimumab (1 mg per kilogram) intravenously every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) every 2 weeks, or sunitinib (50 mg) orally once daily for 4 weeks (6-week cycle). The coprimary end points were overall survival (alpha level, 0.04), objective response rate (alpha level, 0.001), and progression-free survival (alpha level, 0.009) among patients with intermediate or poor prognostic risk. RESULTS: A total of 1096 patients were assigned to receive nivolumab plus ipilimumab (550 patients) or sunitinib (546 patients); 425 and 422, respectively, had intermediate or poor risk. At a median follow-up of 25.2 months in intermediate- and poor-risk patients, the 18-month overall survival rate was 75% (95% confidence interval [CI], 70 to 78) with nivolumab plus ipilimumab and 60% (95% CI, 55 to 65) with sunitinib; the median overall survival was not reached with nivolumab plus ipilimumab versus 26.0 months with sunitinib (hazard ratio for death, 0.63; P<0.001). The objective response rate was 42% versus 27% (P<0.001), and the complete response rate was 9% versus 1%. The median progression-free survival was 11.6 months and 8.4 months, respectively (hazard ratio for disease progression or death, 0.82; P=0.03, not significant per the prespecified 0.009 threshold). Treatment-related adverse events occurred in 509 of 547 patients (93%) in the nivolumab-plus-ipilimumab group and 521 of 535 patients (97%) in the sunitinib group; grade 3 or 4 events occurred in 250 patients (46%) and 335 patients (63%), respectively. Treatment-related adverse events leading to discontinuation occurred in 22% and 12% of the patients in the respective groups. CONCLUSIONS: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma. (Funded by Bristol-Myers Squibb and Ono Pharmaceutical; CheckMate 214 ClinicalTrials.gov number, NCT02231749 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Third, many of these studies utilized ICIs as monotherapy in a heavily pretreated population whereas current standard first-line therapy often includes a combination of ICIs or ICI with chemotherapy for multiple tumor types (35–40).”
From A Uniform Computational Approach Improved on Existing Pipelines to Reveal Microbiome Biomarkers of Nonresponse to Immune Checkpoint Inhibitors (2021) · cites this paper as [40]
Experimental — accuracy not yet measuredIn the citing paper
“In that study, patients were randomized either to that regimen or to sunitinib (a VEGF inhibitor); significant prolongation of PFS and overall survival was observed, with 42% of patients achieving a response (many of these durable)11,12.”
From Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial (2022) · cites this paper as [11]
In the citing paper
“Anti-PD-1/PD-L1 agents pared with chemotherapy have also improved response rates and survival in many diseases including lung cancer, triple negative breast cancer, head and neck squamous cell carcinoma, and others.12–14”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationCombined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · cited 1×
“Bone§ 95 (22) 97 (23) 112 (20) 119 (22)”
Self-citationSunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775 · cited 1×
“Diarrhea 145 (27) 21 (4) 278 (52) 28 (5)”
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 4×
“Female 111 (26) 121 (29) 137 (25) 151 (28)”
InfluentialTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
CLOPPER, C. J., & PEARSON, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,003 · cited 1×
“Bone§ 95 (22) 97 (23) 112 (20) 119 (22)”
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“Decreased appetite 75 (14) 7 (1) 133 (25) 5 (<1)”
Cited by
Items 601–700 of 1,016
Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy
Caster, J. M., Callaghan, C. M., Seyedin, S. N., Henderson, K., Sun, B., & Wang, A. Z. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.07.009 · Cited by 56
Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma
Bacon, J. V. W., Annala, M., Soleimani, M., Lavoie, J., So, A., Gleave, M. E., Fazli, L., Wang, G., Chi, K. N., Kollmannsberger, C., et al. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.12.018 · Cited by 58
Self-citationTryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1
Botticelli, A., Mezi, S., Pomati, G., Cerbelli, B., Cerbelli, E., Roberto, M., Giusti, R., Cortellini, A., Lionetto, L., Scagnoli, S., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01243 · Cited by 56
“In the near future, immunotherapy will change the first-line standard of care of metastatic RCC on the basis of the results from a more recent phase III trial evaluating the combination of nivolumab and the anti-CTLA-4 monoclonal antibody ipilimumab (9).”
BackgroundProcopio, G., Claps, M., Pircher, C. C., Porcu, L., Sepe, P., Guadalupi, V., Giorgi, U. D., Bimbatti, D., Nolè, F., Carrozza, F., et al. (2022) · Tumori Journal · doi:10.1177/03008916221138881 · Cited by 58
Surgical Management of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus
Dason, S., Mohebali, J., Blute, M. L., & Salari, K. (2023) · Urologic Clinics of North America · doi:10.1016/j.ucl.2023.01.007 · Cited by 54
Lin, Z., Liu, L., Xia, Y., Chen, X., Xiong, Y., Qu, Y., Wang, J., Bai, Q., Guo, J., & Xu, J. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1477461 · Cited by 65
“Even so, the response rates to anti-PD-1 antibody were only 27%, which is far from satisfied, in patients with renal cancer.(33) Predictive biomarkers exist to guide selection for immune checkpoint inhibitors are still not routinely used in the clinic yet.”
BackgroundHall, E. T., Singhal, S., Dickerson, J. C., Gabster, B. P., Wong, H.-N., Aslakson, R. A., Schapira, L., Aslakson, R. A., Ast, K., Carroll, T., et al. (2019) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2019.03.015 · Cited by 59
Nivolumab Plus Ipilimumab in Non-Small-Cell Lung Cancer
Reck, M., Borghaei, H., & O'Byrne, K. J. (2019) · Future Oncology · doi:10.2217/fon-2019-0031 · Cited by 58
“In intermediate- and poor-risk patients with previously untreated advanced renal-cell carcinoma, OS was significantly longer and the objective response rate (ORR) significantly higher with nivolumab plus ipilimumab than sunitinib [64].”
BackgroundResultOvercoming immunotherapeutic resistance by targeting the cancer inflammation cycle
Wattenberg, M. M., & Beatty, G. L. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.002 · Cited by 59
“For instance, even in cancers where immunotherapy has demonstrated remarkable activity, such as non-small cell lung cancer (NSCLC) [1-4], kidney cancer [5-7], and melanoma [8, 9], many patients do not respond or ultimately relapse after initial disease control.”
BackgroundHarnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers
Maia, M. C., Salgia, M. M., & Pal, S. K. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0297-9 · Cited by 62
PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy
Zahm, C. D., Moseman, J. E., Delmastro, L. E., & McNeel, D. G. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1912892 · Cited by 57
“Similar results in patients with renal cell cancer have led to the FDA approval of CTLA-4 and PD-1 dual blockade for the treatment of metastatic renal cell cancer and melanoma.(14,15) In previous studies, we found that DNA or peptide vaccineinduced activation of tumor-specific, CD8 + T cells led to increased expressio…”
ResultEmerging Management Approach for the Adverse Events of Immunotherapy of Cancer
Rahman, M. M., Behl, T., Islam, M. R., Alam, M. N. A., Islam, M. M., Albarrati, A., Albratty, M., Meraya, A. M., & BUNGAU, S. G. (2022) · Molecules · doi:10.3390/molecules27123798 · Cited by 57
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Roy, D., Gilmour, C., Patnaik, S., & Wang, L. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264327 · Cited by 53
Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective
Lavacchi, D., Pellegrini, E., Palmieri, V. E., Doni, L., Mela, M. M., Maida, F. D., Amedei, A., Pillozzi, S., Carini, M., & Antonuzzo, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134691 · Cited by 57
“0%, respectively, in the first and second line [24].”
BackgroundAdjuvant therapy in renal cell carcinoma: Current knowledges and future perspectives
Larroquette, M., Peyraud, F., Domblides, C., Lefort, F., Bernhard, J., Ravaud, A., & Gross‐Goupil, M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102207 · Cited by 65
Self-citationA single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma
Kourtis, N., Wang, Q., Wang, B., Oswald, E. M., Adler, C., Cherravuru, S., Malahias, E., Zhang, L., Golubov, J., Wei, Q., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00391-0 · Cited by 58
Immunosenescence, inflammaging, and cancer immunotherapy efficacy
Rodriguez, J. E., Naigeon, M., Goldschmidt, V., Dugage, M. R., Seknazi, L., Danlos, F., Champiat, S., Marabelle, A., Michot, J., Massard, C., et al. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2098718 · Cited by 57
Watanabe, T., Ishino, T., Ueda, Y., Nagasaki, J., Sadahira, T., Dansako, H., Araki, M., & Togashi, Y. (2023) · Cancer Science · doi:10.1111/cas.15756 · Cited by 60
Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities
Barroso‐Sousa, R., Pacifico, J. P. M., Sammons, S. L., & Tolaney, S. M. (2023) · Cancers · doi:10.3390/cancers15153997 · Cited by 58
Immune checkpoint inhibitors in bone metastasis: Clinical challenges, toxicities, and mechanisms
Joseph, G. J., Johnson, D. B., & Johnson, R. W. (2023) · Journal of bone oncology · doi:10.1016/j.jbo.2023.100505 · Cited by 58
“Ipi/Nivo combination therapy increases the prevalence and severity of irAEs over treatment with a single agent [76]; depending on the primary tumor type, the prevalence of severe irAEs in patients receiving combination therapy can range from 46% to 55% [78 – 80].”
BackgroundHugaboom, M. B., Wirth, L. V., Street, K., Ruthen, N. G., Jegede, O. A., Schindler, N. R., Shah, V., Zaemes, J. P., Ahmar, N. E., Matar, S., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0991 · Cited by 63
Self-citationCost effectiveness vs. affordability in the age of immuno-oncology cancer drugs
Dranitsaris, G., Zhu, X., Adunlin, G., & Vincent, M. D. (2018) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2018.1467270 · Cited by 55
Liu, Y. L., & Zamarin, D. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0740-8 · Cited by 56
Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors
Chen, Z., Yang, Y., Liu, L. L., & Lundqvist, A. (2019) · Cancers · doi:10.3390/cancers11071040 · Cited by 53
Soldevilla, M. M., Villanueva, H., Meraviglia-Crivelli, D., Menon, A. P., Ruiz, M., Cebollero, J., Villalba-Esparza, M., Moreno, B., Lozano, T., Llópiz, D., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.07.013 · Cited by 53
Suzuki, K., Terakawa, T., Furukawa, J., Harada, K., Hinata, N., Nakano, Y., & Fujisawa, M. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01528-5 · Cited by 58
“In addition, therapeutic options have further expanded to include the combination of ICIs, such as nivolumab and ipilimumab, an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody [3].”
BackgroundThe Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Tunger, A., Sommer, U. J., Wehner, R., Kubasch, A. S., Grimm, M., Bachmann, M. P., Platzbecker, U., Bornhäuser, M., Baretton, G. B., & Schmitz, M. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101534 · Cited by 55
Self-citationDougan, M. L., Blidner, A. G., Choi, J. N., Cooksley, T., Glezerman, I. G., Ginex, P., Girotra, M., Gupta, D., Johnson, D. B., Shannon, V. R., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05707-3 · Cited by 57
Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
Louedec, F. L., Leenhardt, F., Marin, C., Chatelut, É., Evrard, A., & Ciccolini, J. (2020) · Vaccines · doi:10.3390/vaccines8040632 · Cited by 62
“This combination was then approved for advanced renal cell carcinoma [91], for previously treated microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) colorectal cancer [92], and, most recently, for hepatocellular carcinoma previously treated with sorafenib [93].”
BackgroundDefining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Michielin, O. A., Lalani, A. A., Robert, C., Sharma, P., & Peters, S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003024 · Cited by 64
Self-citationNext-generation cancer vaccines and emerging immunotherapy combinations
Brandenburg, A., Heine, A., & Brossart, P. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.06.003 · Cited by 58
Li, D., Li, C., Chen, Y., Teng, L. L., Cao, Y. W., Wang, W., Pan, H., Xu, Y., & Yang, D. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01419-0 · Cited by 52
La, J., Cheng, D. T.-Y., Brophy, M. T., Do, N., Lee, J. S. H., Tuck, D. P., & Fillmore, N. R. (2020) · JCO Clinical Cancer Informatics · doi:10.1200/cci.20.00084 · Cited by 55
Current concepts of non-coding RNA regulation of immune checkpoints in cancer
Smolle, M. A., Prinz, F., Calin, G. A., & Pichler, M. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.09.007 · Cited by 52
Ambrosetti, D., Coutts, M., Paoli, C., Durand, M., Borchiellini, D., Montemagno, C., Rastoin, O., Borderie, A., Grépin, R., Rioux-Leclercq, N. C., et al. (2021) · British Journal of Urology · doi:10.1111/bju.15506 · Cited by 64
Davar, D., Zappasodi, R., Wang, H., Naik, G. S., Sato, T., Bauer, T. M., Bajor, D. L., Rixe, O., Newman, W., Qi, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0339 · Cited by 56
Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
Seto, T., Sam, D. L., & Pan, M. (2019) · Medical Sciences · doi:10.3390/medsci7020014 · Cited by 59
“The combination of low-dose ipilimumab with nivolumab has shown added activities in melanoma, renal cell carcinoma, and non-small cell lung cancer with high TMB with improved PFS and OS [81,110,111].”
BackgroundOperative and peri‐operative considerations in the management of brain metastasis
Sankey, E. W., Tsvankin, V., Grabowski, M. M., Nayar, G., Batich, K. A., Risman, A., Champion, C. D., Salama, A. K. S., Goodwin, C. R., & Fecci, P. E. (2019) · Cancer Medicine · doi:10.1002/cam4.2577 · Cited by 51
Giesen, D., Broer, L. N., Hooge, M. N. L., Popova, I., Howng, B., Nguyen, M. T. L., Vasiljeva, O. S., de Vries, E. G. E., & Pool, M. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3137 · Cited by 54
Dutcher, J. P., Flippot, R., Fallah, J., & Escudier, B. J. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280817 · Cited by 61
Self-citationImmune cell composition in normal human kidneys
Park, J.-G., Na, M., Kim, M.-G., Park, S. H., Lee, H. J., Kim, D. K., Kwak, C. H., Kim, Y. S., Chang, S., Moon, K. C., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-72821-x · Cited by 60
Immunotherapy to treat malignancy in patients with pre-existing autoimmunity
Boland, P., Pavlick, A. C., Weber, J., & Sandigursky, S. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000356 · Cited by 50
Wiksten, A. S., Hawkins, N., Piepho, H., & Gsteiger, S. (2020) · Value in Health · doi:10.1016/j.jval.2020.03.010 · Cited by 54
French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer
Bigot, P., Barthélémy, P., Boissier, R., Khene, Z., Pettenati, C., Bernhard, J., Corréas, J.-M., Doumerc, N., Gimel, P., Ingels, A., et al. (2022) · The French Journal of Urology · doi:10.1016/j.purol.2022.07.146 · Cited by 56
Self-citationAkkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy
Fan, S., Jiang, Z., Zhang, Z., Xing, J., Wang, D., & Tang, D. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05199-8 · Cited by 53
Salvato, I., & Marchini, A. (2024) · Cancers · doi:10.3390/cancers16071276 · Cited by 56
Small-Molecule Targets in Tumor Immunotherapy
Zhu, H., & Li, Y. (2018) · Natural Products and Bioprospecting · doi:10.1007/s13659-018-0177-7 · Cited by 51
The Identification of Immunological Biomarkers in Kidney Cancers
López-Beltrán, A., Henriques, V., Cimadamore, A., Santoni, M., Cheng, L., Gevaert, T., Blanca, A., Massari, F., Scarpelli, M., & Montironi, R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00456 · Cited by 56
“In summary, better understanding the predictive and prognostic significance of PD1/PD-L1 expression and the identification of molecularly defined subtypes correlated with survival and response to therapy, represent quick steps toward implementing precision medicine in RCC via reducing the distance to the goal of ident…”
BackgroundGrünwald, V., Powles, T. B., Choueiri, T. K., Hutson, T. E., Porta, C., Eto, M., Sternberg, C. N., Rha, S. Y., He, C. S., Dutcus, C. E., et al. (2019) · Future Oncology · doi:10.2217/fon-2018-0745 · Cited by 50
Self-citationUEDA, K., YONEKURA, S., OGASAWARA, N., MATSUNAGA, Y., HOSHINO, R., KUROSE, H., CHIKUI, K., UEMURA, K., NAKIRI, M., NISHIHARA, K., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13836 · Cited by 48
Current State of Systemic Therapies for Advanced Renal Cell Carcinoma
Gulati, S., & Vaishampayan, U. N. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-0892-1 · Cited by 58
Sheng, I. Y. F., & Ornstein, M. C. (2020) · Cancer Management and Research · doi:10.2147/cmar.s202017 · Cited by 53
Ged, Y. M. A., Chaim, J. L., DiNatale, R. G., Knežević, A., Kotecha, R. R., Carlo, M. I., Lee, C., Foster, A., Feldman, D. R., Teo, M. Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000230 · Cited by 58
Self-citationPredicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma
Tucker, M. D., & Rini, B. I. (2020) · Cancers · doi:10.3390/cancers12092662 · Cited by 56
Self-citationWang, J., Zou, Y., Du, B., Li, W., Yu, G., Li, L., Zhou, L., Gu, X., Song, S., Liu, Y., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-03958-4 · Cited by 51
McGregor, B. A., Mortazavi, A., Cordes, L. M., Salabao, C., Vandlik, S., & Apolo, A. B. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102333 · Cited by 56
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Sanmamed, M. F., Berraondo, P., Rodriguez-Ruiz, M. E., & Melero, I. (2022) · Nature Cancer · doi:10.1038/s43018-022-00401-1 · Cited by 53
The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma
Garje, R., An, J., Greco, A., Vaddepally, R. K., & Zakharia, Y. (2020) · Cancers · doi:10.3390/cancers12010143 · Cited by 50
“In Checkmate 214, a Phase III randomized open-label multicenter trial, nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) was compared with sunitinib monotherapy (50 mg daily for 4 weeks on and 2 weeks off every cycle) in patients with treatment naïve metastatic ccRCC [11] (summarized in Table 1).”
BackgroundMethodPignot, G., Thiery-Vuillemin, A., Albiges, L. K., Walz, J. C., Lang, H., Balssa, L., Parier, B., Geoffrois, L., Bensalah, K., Schlürmann, F., et al. (2022) · European Urology Oncology · doi:10.1016/j.euo.2022.07.002 · Cited by 49
Self-citationSové, R. J., Verma, B. K., Wang, H., Ho, W. J., Yarchoan, M. M., & Popel, A. S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005414 · Cited by 56
Resistance to immune checkpoint inhibitors and the tumor microenvironment
Kawashima, S., & Togashi, Y. (2022) · Experimental Dermatology · doi:10.1111/exd.14716 · Cited by 55
Focused ultrasound-assisted delivery of immunomodulating agents in brain cancer
Memari, E., Khan, D. S., Alkins, R. D., & Helfield, B. L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.034 · Cited by 51
Qiu, J., Cheng, Z., Jiang, Z., Gan, L., Zhang, Z., & Xie, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105490 · Cited by 59
“Ipilimumab, a mAb functioning as a CTLA-4 inhibitor, was initially approved for treating metastatic melanoma in 2011 [75].”
BackgroundBarata, P. C., de Liaño, A. G., Mendiratta, P., Crolley, V. E., Szabados, B. E., Morrison, L., Wood, L. S., Allman, K. D., Tyler, A. J., Martin, A. M., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0104-z · Cited by 51
Self-citationAsaka, S., Yen, T., Wang, T., Shih, I., & Gaillard, S. L. (2018) · Modern Pathology · doi:10.1038/s41379-018-0172-x · Cited by 50
Fishman, M., Dutcher, J. P., Clark, J. I., Alva, A. S., Miletello, G. P., Curti, B. D., Agarwal, N., Hauke, R. J., Mahoney, K. M., Moon, H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0567-3 · Cited by 49
Self-citationTargeting Tyrosine kinases in Renal Cell Carcinoma: “New Bullets against Old Guys”
Alonso‐Gordoa, T., García‐Bermejo, L., Grande, E., Garrido, P., Carrato, A., & Molina‐Cerrillo, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081901 · Cited by 55
“For example, the inhibition of the mTORC complex by everolimus or temsirolimus presented benefits in a selected patients ́ population and new immunotherapy strategies, such as nivolumab or its combination with ipilimumab, presented positive results in terms of efficacy and survival post VEGF-therapy and in the first l…”
BackgroundTherapeutic Targeting of Autophagy for Renal Cell Carcinoma Therapy
Jones, T. M., Carew, J. S., & Nawrocki, S. T. (2020) · Cancers · doi:10.3390/cancers12051185 · Cited by 51
Silva, P. D., Aiello, M. M., Gu‐Trantien, C., Migliori, E., Willard-Gallo, K. E., & Solinas, C. (2020) · International Journal of Cancer · doi:10.1002/ijc.33415 · Cited by 50
“clinical benefits similar to those observed in CheckMate 067 for the treatment of metastatic melanoma patients.(107) CheckMate 214 was a randomized Phase III trial which the combo vs sunitinib in previously untreated metastatic RCC patients.”
ResultLin, E., Liu, X., Liu, Y., Zhang, Z., Xie, L., Tian, K., Liu, J., & Yu, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.653358 · Cited by 59
Gan, C. L., Stukalin, I., Meyers, D. E., Dudani, S., Grosjean, H. A. I., Dolter, S., Ewanchuk, B. W., Goutam, S., Sander, M. S., Wells, J. C., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.004 · Cited by 50
Self-citationChakiryan, N. H., Jiang, D. D., Gillis, K. A., Green, E., Hajiran, A. J., Hugar, L. A., Zemp, L. W., Zhang, J., Jain, R., Chahoud, J., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.11329 · Cited by 53
Morimoto, K., Uchino, J., Yokoi, T., Kijima, T., Gotô, Y., Nakao, A., Hibino, M., Takeda, T., Yamaguchi, H., Takumi, C., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1950411 · Cited by 52
Hong, M. M. Y., & Vareki, S. M. (2022) · Cancers · doi:10.3390/cancers14061580 · Cited by 54
“NCT02231749 [115] Advanced renal cell carcinoma Sunitinib (n = 422) 26.”
BackgroundUncovering axes of variation among single-cell cancer specimens
Chen, W. S., Zivanovic, N., van Dijk, D., Wolf, G., Bodenmiller, B., & Krishnaswamy, S. (2020) · Nature Methods · doi:10.1038/s41592-019-0689-z · Cited by 48
“The detection of a subset of patients with exhausted T cell enrichment may be of particular clinical interest, as immunotherapy agents that combat T-cell exhaustion have become a mainstay of advanced-stage ccRCC treatment, but patients continue to have highly variable treatment responses 36,37 .”
BackgroundZhang, W., Shi, F., Kong, Y., Li, Y., Sheng, C., Wang, S., & Wang, Q. (2021) · Cancer Medicine · doi:10.1002/cam4.4472 · Cited by 59
“Previously reported immune- related signatures were collected as follows: (1) immune and stromal cells signatures, which respectively reflect the total immune and stromal cell infiltration levels in microenvironment40; (2) immune cell subsets, enrichment of T cells, B cells, and NK cells41; (3) T/NK, B/P, and M/D meta…”
MethodZhou, X., Khan, S. H., Huang, D., & Li, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.938470 · Cited by 57
Wu, L., Zhang, Z., Bai, M., Yan, Y., Yu, J., & Xu, Y. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01139-8 · Cited by 53
Comprehensive proteogenomic characterization of rare kidney tumors
Li, G. X., Chen, L., Hsiao, Y., Mannan, R., Zhang, Y., Luo, J., Petralia, F., Cho, H., Hosseini, N., Leprevost, F. D. V., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101547 · Cited by 62
Rini, B. I., Hutson, T. E., Figlin, R. A., Lechuga, M. J., Valota, O., Serfass, L., Rosbrook, B., & Motzer, R. J. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.04.005 · Cited by 48
“The CheckMate-214 data are more consistent with the present analysis, albeit with a slightly lower ORR and lower PFS.(13) Overall survival data in the present analysis are numerically lower than data reported in more recent trials(12) and are likely not reflective of current expectations because of the greatly expande…”
MethodResultInfluentialSelf-citationThe Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma
Calvo, E., Porta, C., Grünwald, V., & Escudier, B. J. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0267 · Cited by 48
“IMMUNE CHECKPOINT INHIBITORS Combination therapy with the immune checkpoint inhibitor antibodies nivolumab and ipilimumab was recently shown to be effective in the first-line setting in the phase III CheckMate-214 study [32].”
BackgroundMethodResultInfluentialSelf-citationFan, Q., Hu, Y., Yang, C., & Zhao, B. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105866 · Cited by 52
Emerging therapeutic agents for genitourinary cancers
Zarrabi, K. K., Paroya, A., & Wu, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0780-z · Cited by 51
“There was no significant difference in mPFS [82].”
BackgroundLow doses in immunotherapy: Are they effective?
Prabhash, K., Patil, V. M., Noronha, V., Joshi, A. D., Abhyankar, A. V., Menon, N. S., Banavali, S. D., & Gupta, S. (2019) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_29_19 · Cited by 51
Ninomiya, K., Oze, I., Kato, Y., Kubo, T., Ichihara, E., Rai, K., Ohashi, K., Kozuki, T., Tabata, M., Maeda, Y., et al. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1695062 · Cited by 54
Checkpoint inhibitors in AML: are we there yet?
Ghosh, A., Barba, P., & Perales, M. (2019) · British Journal of Haematology · doi:10.1111/bjh.16358 · Cited by 60
Immune checkpoint: The novel target for antitumor therapy
Jiang, X., Liu, G., Li, Y., & Pan, Y. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.12.004 · Cited by 54
“combined with ipilimumab is more effective than sunitinib in treating advanced renal cell carcinoma, with higher overall survival and lower incidence of immune-related adverse events.(110,111) On April 16, 2018, the FDA approved the combination of nivolumab and ipilimumab for the treatment of advanced renal cell carci…”
BackgroundKitagataya, T., Suda, G., Nagashima, K., Katsurada, T., Yamamoto, K., Kimura, M., Maehara, O., Yamada, R., Shigesawa, T., Suzuki, K., et al. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15041 · Cited by 52
Grover, S., Ruan, A. B., Srivoleti, P. D., Giobbie‐Hurder, A., Braschi‐Amirfarzan, M., Srivastava, A., Buchbinder, E. I., Ott, P. A., Kehl, K. L., Awad, M. M., et al. (2020) · JCO Oncology Practice · doi:10.1200/jop.19.00672 · Cited by 52
Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma
Attalla, K., Weng, S., Voss, M. H., & Hakimi, A. A. (2020) · Urologic Clinics of North America · doi:10.1016/j.ucl.2020.04.002 · Cited by 58
König, D., & Laubli, H. P. (2020) · Pharmacology · doi:10.1159/000509081 · Cited by 54
Kobayashi, Y., Kushihara, Y., Saito, N., Yamaguchi, S., & Kakimi, K. (2020) · Cancer Science · doi:10.1111/cas.14621 · Cited by 60
The dark side of immunotherapy
Okwundu, N., Grossman, D., Hu‐Lieskovan, S., Grossmann, K. F., & Swami, U. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-4750 · Cited by 52
Response to systemic therapy in fumarate hydratase–deficient renal cell carcinoma
Carril-Ajuria, L., Colomba, É., Cerbone, L., Romero, C., Crouzet, L., Laguerre, B., Thibault, C., Vicier, C., de Velasco, G., Fléchon, A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.04.009 · Cited by 51
Self-citationWhat Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang, Q., Xie, B., Liu, S., Shi, Y., Tao, Y., Xiao, D., & Wang, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.773168 · Cited by 51
“Also, nivolumab has been demonstrated durable effects in other cancers (47, 64, 65), and it appears that combination therapy may further improve them (50, 66).”
BackgroundChen, Z., Liu, X., Zhu, Z., Chen, J., Wang, C., Chen, X., Zhu, S., & Zhang, A. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1039465 · Cited by 47
“However, more than half of the patients could not achieve the long-term response to PD-1-related treatment (Motzer et al., 2018).”
BackgroundCHI3L1 enhances melanoma lung metastasis via regulation of T cell co-stimulators and CTLA-4/B7 axis
Ma, B., Kamle, S., Akosman, B., Khan, H., Lee, C.-M., Lee, C. G., & Elias, J. A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1056397 · Cited by 49
“Bispecific antibodies that simultaneously target CHI3L1 and CTLA-4 synergistically induce CTL cell differentiation, PTEN expression and tumor cell death In recent years it has become clear that combination therapy with ICP blockers can induce particularly potent responses in a variety of tumors including lung cancers…”
BackgroundChasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery
Colombo, I., Karakasis, K., Sneha, S., & Oza, A. M. (2023) · Cancers · doi:10.3390/cancers15123220 · Cited by 53
“The combination of anti-PD-1/PD-L1 with anti-CTL-4 is another effective strategy that has been pursued with positive results in different solid tumors, showing an increased efficacy with a dual checkpoints inhibition [26,27,87,88].”
BackgroundImmune Checkpoint Inhibitors and Glioblastoma: A Review on Current State and Future Directions
Ser, M. H., Webb, M., Sener, U. T., & Campian, J. L. (2024) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-23-34 · Cited by 56
Immunotherapy resistance in solid tumors: mechanisms and potential solutions
Lefler, D. S., Manobianco, S. A., & Bashir, B. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2315655 · Cited by 55
“Therefore, overcoming inhibitory check-point resistance largely relies on increasing antigen presentation/recognition, modulating the balance of cytokines, targeting multiple checkpoints simultaneously, and reducing the effect of immunosuppressive tumor-associated macrophages (TAMs) and MDSCs. 77 More recently, relatl…”
BackgroundInfluential
Metadata
- Authors
- Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., Powles, T., Donskov, F., Neiman, V., Kollmannsberger, C. K., Salman, P., Gurney, H., Hawkins, R., Ravaud, A., Grimm, M.-O., Bracarda, S., Barrios, C. H., Tomita, Y., Castellano, D., Rini, B. I., Chen, A. C., Mekan, S., McHenry, M. B., Wind-Rotolo, M., Doan, J., Sharma, P., Hammers, H. J., & Escudier, B.
- Affiliations
- Brigham and Women's Hospital (US)
- From Memorial Sloan Kettering Cancer Center, New York (R.J.M.), and Roswell Park Cancer Institute, Buffalo (S.G.) — both in New York; University of Texas M.D. Anderson Cancer Center, Houston (N.M.T., P. Sharma); Beth Israel Deaconess Medical Center, Dana–Farber/Harvard Cancer Center (D.F.M.), and Dana–Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School (T.K.C.), Boston; Centro Internacional de Estudios Clínicos (O.A.F.) and Fundación Arturo López Pérez (P. Salman),...
- ORCID
- Motzer, Robert J.
- Tannir, Nizar M.
- McDermott, David F.
- Melichar, Bohuslav
- Choueiri, Toni K.
- Plimack, Elizabeth R.
- Barthélémy, Philippe
- Porta, Camillo
- George, Saby
- Powles, Thomas
- Donskov, Frede
- Kollmannsberger, Christian K.
- Salman, Pamela
- Gurney, Howard
- Ravaud, Alain
- Grimm, Marc-Oliver
- Barrios, Carlos H.
- Tomita, Yoshihiko
- Castellano, Daniel
- Rini, Brian I.
- Mekan, Sabeen
- McHenry, M. Brent
- Sharma, Padmanee
- Hammers, Hans J.
- Escudier, Bernard
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-04-05
- Volume
- 378
- Issue
- 14
- Pages
- 1277-1290
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5972549
- OpenAlex
- W2792937256
- Cited by
- 4,656
- References
- 31
- Citations by year
- 2026: 305 · 2025: 416 · 2024: 510 · 2023: 601 · 2022: 656 · 2021: 708 · 2020: 684 · 2019: 562 · 2018: 209
- FWCI
- 408.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
- Tampere University Institutional Repository (Tampere University) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- Ono Pharmaceutical Company Limited
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- nivolumab plus ipilimumab, sunitinib, advanced renal cell carcinoma, clear cell renal cell carcinoma, immune checkpoint inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, combination immunotherapy, overall survival, objective response rate, progression-free survival, treatment-related adverse events, immune-related adverse events, first-line therapy
- MeSH terms
- Antineoplastic Agents, Immunological, Ipilimumab, Sunitinib, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Humans, Indoles, Kidney Neoplasms, Male, Middle Aged, Pyrroles, Quality of Life, Risk, Survival Rate, Survival Analysis, Disease-Free Survival
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.